Transplant Infectious Diseases: A Review of the Scientific Registry of Transplant Recipients Published Data

American Journal of Transplantation

Volumn 17, Issue 6, 2017, Pages 1439-1446

  Kotton, C N ^a   Huprikar, S ^b   Kumar, D ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

clinical research practice; health services and outcomes research; infection and infectious agents; infectious disease; posttransplant lymphoproliferative disorder (PTLD); viral: cytomegalovirus (CMV); viral: Epstein Barr virus (EBV); viral: hepatitis; viral: human immunodeficiency virus (HIV) acquired immunodeficiency syndrome (AIDS)

Indexed keywords

ANTIINFECTIVE AGENT; VALGANCICLOVIR;

CYTOMEGALOVIRUS; DONOR SELECTION; DRUG USE; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; COMMUNICABLE DISEASE; ETHICS; ORGAN TRANSPLANTATION; REGISTER; RISK FACTOR;

COMMUNICABLE DISEASES; HUMANS; ORGAN TRANSPLANTATION; REGISTRIES; RISK FACTORS; TRANSPLANT RECIPIENTS;

EID: 85013678895     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14195     Document Type: Review

References (36)

1. UNOS TIEDI [cited 2017 Feb 5]. Available from: https://www.unos.org/data/history-of-database/.
2. The Scientific Registry of Transplant Recipients. [cited 2017 Feb 5]. Available from: http://srtr.transplant.hrsa.gov.
3. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004. Clin Infect Dis 2010; 50: 1439–1447.
4. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: Kidney. Am J Transplant 2015; 15(Suppl 2): 1–34.
5. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840–846.
6. Dzabic M, Rahbar A, Yaiw KC, et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011; 53: 969–976.
7. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87: 436–444.
8. Dowd JB, Palermo T, Brite J, McDade TW, Aiello A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003–2010. PLoS ONE 2013; 8: e64921.
9. San-Juan R, Manuel O, Hirsch HH, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect 2015; 21: 604.e1–604.e9.
10. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 2012; 27: 2971–2979.
11. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206–209.
12. Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative disorders after adult kidney transplant: Epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis 2011; 58: 971–980.
13. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management. Am J Transplant 2015; 15: 1162–1172.
14. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261–283.
15. Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation 2015; 99: 1192–1196.
16. Suryaprasad A, Basavaraju SV, Hocevar SN, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant 2015; 15: 1827–1835.
17. Ison MG, Llata E, Conover CS, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11: 1218–1225.
18. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004–2014.
19. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716–726.
20. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10: 1268–1275.
21. Locke JE, Reed RD, Mehta SG, et al. Center-level experience and kidney transplant outcomes in HIV-infected recipients. Am J Transplant 2015; 15: 2096–2104.
22. Locke JE, Mehta S, Reed RD, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol 2015; 26: 2222–2229.
23. Locke JE, Durand C, Reed RD, et al. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients. Transplantation 2016; 100: 141–146.
24. Sims DB, Uriel N, Gonzalez-Costello J, et al. Human immunodeficiency virus infection and left ventricular assist devices: A case series. J Heart Lung Transplant 2011; 30: 1060–1064.
25. Krishan K, Pinney S, Anyanwu AC. Successful left ventricular assist device bridge to transplantation in a patient with end-stage heart failure and human immunodeficiency virus. Artif Organs 2012; 36: 759.
26. He SY, Makhzoumi ZH, Singer JP, Chin-Hong PV, Arron ST. Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: A national survey. Transpl Infect Dis 2015; 17: 14–20.
27. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR Annual Data Report 2014: Liver. Am J Transplant 2006; 16(Suppl 2): 69–98. doi: 10.1111/ajt.13668
28. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8: 158–161.
29. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779–795.
30. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761–769.
31. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228–1237.
32. Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant 2016; 16(Suppl 2): 11–46.
33. Green M. Introduction: Infections in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 3–8.
34. Fishman JA; AST Infectious Diseases Community of Practice. Introduction: Infection in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S3–S6.
35. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333–360.
36. Humar A, Lebranchu Y, Vincenti F, et al, editors. The IMPACT Study: Valganciclovir Prophylaxis for Until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease (abstract). Boston, MA: American Transplant Congress; 2009.